SUMMIT THERAPEUTICS PLC reports a Return on Equity (ROE) of -135.89%.

What is SMMT's dividend yield?

SUMMIT THERAPEUTICS PLC offers a dividend yield of 0.00%.

What is SMMT's Quality Score?

Our AI rates SMMT's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy SMMT?

Our AI Timing Score for SMMT is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does SMMT belong to?

SUMMIT THERAPEUTICS PLC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

SMMT (NASDAQ) Stock Analysis | SUMMIT THERAPEUTICS PLC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-06-30)

SMMT AI Analysis Summary

Our AI summary for SMMT: SUMMIT THERAPEUTICS PLC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -135.89%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

SMMT

SUMMIT THERAPEUTICS PLC

US:NASDAQ STOCK Healthcare >> Biotechnology News 96

USD 13.02

-0.42 (-3.13%) Day Change

Watchlist Portfolio Compare Chart

0.01

D/E

-135.9%

ROE

-113.8%

ROA

0.00%

Div Yield

SUMMIT THERAPEUTICS PLC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 13.02 Price -0.42 (-3.13%) Day Change	NEWS SCORE: 96

SMMT, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	96
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	13.02
PBV / Sector	17.02 / 5.20
Earning Per Share	-1.04

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	51.61 M
Average 1W Daily Value	53.67 M

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

47%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

47%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 98.71
NPM Average (%) / Sector	-11,174.75 / -1,721.76
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-113.81 / 27.02
ROA Average (%) / Sector	-134.13 / -368.17
ROA Change Average (%) / Sector	638.05 / 5,404.12 GREAT
ROE (%) / Sector	-135.89 / 3.47
ROE Average (%) / Sector	-252.25 / 6.51
ROE Change Average (%) / Sector	324.94 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 08:00:29
Symbol	SMMT
Name	SUMMIT THERAPEUTICS PLC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	797.75 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	10,721.76 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 601 Brickell Key Drive, Miami, FL, United States, 33131

Phone: 305 203 2034

Website: https://www.smmttx.com

Employees: 265

Sector: Healthcare >> Biotechnology

Description: Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.